semaglutide vs tirzepatide

semaglutide (S-tier) vs tirzepatide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

semaglutide — tier S

ozempic. wegovy. rybelsus. the GLP-1 drug that made obesity a pharmacology problem.

the GLP-1 that broke containment. ozempic, wegovy, rybelsus. same molecule, three labels.

14.9% STEP 1 wt loss · half-life ~1 week (acylated) · weight loss

tirzepatide — tier S

mounjaro and zepbound. GLP-1 plus GIP dual agonist. beats semaglutide head-to-head on weight loss.

the dual GLP-1/GIP agonist that beat semaglutide head-to-head. mounjaro for diabetes, zepbound for obesity, same molecule.

22.5% SURMOUNT-1 wt loss · half-life ~5 days · weight loss

at a glance

• semaglutide: tier S · 14.9% STEP 1 wt loss
• tirzepatide: tier S · 22.5% SURMOUNT-1 wt loss

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.